Abstract
The safety and immunogenicity of two PorA-based meningococcal outer membrane vesicle (OMV) vaccines against the P1.4 serosubtype adsorbed with AlPO 4 or Al(OH) 3 were studied in 134 toddlers. Vaccinations were given three times with an interval of 3–6 weeks or twice with an interval of 6–10 weeks. A vaccination was repeated after 20–40 weeks. Pre- and post-immunization sera were tested for bactericidal activity against an isogenic strain expressing P1.7 h,4 PorA. Both meningococcal OMV vaccines were well tolerated. The percentage of children with a fourfold increase in bactericidal activity was 96% (AlPO 4-adjuvated vaccine/2+1 schedule), 100% (AlPO 4-adjuvated vaccine/3+1 schedule), 93% (Al(OH) 3-adjuvated vaccine/2+1 schedule) and 97% (Al(OH) 3-adjuvated vaccine/3+1 schedule). Adsorption with AlPO 4 makes the OMV vaccine more immunogenic than adsorption with Al(OH) 3. Bactericidal activity was highest after the 3+1 schedule, although the response shortly after the primary series was higher in the two-dose priming group.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
